BEDFORD, Mass., October 29, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the third quarter ended September 30, 2026, and provided business updates including progress of the global
Explore Stoke Therapeutics (STOK) ahead of the 2027 zorevunersen Dravet readout—cash runway to 2028, FDA endpoint edge, and upside valuation.
BEDFORD, Mass., October 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Com
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Stoke Therapeutics (STOK) said Monday it has completed a successful meeting with the US Food and Dru
BEDFORD, Mass., October 05, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successful meeting with the U.S. Food and Drug Administration (FDA) intended to align on key aspects of the
BEDFORD, Mass., September 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on September 15, 2026, it granted stock options to purchase an aggregate of 53,175 shares of common stock to
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines– –New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)– –Improvements in quality of life were demonstrated through 28 months of treatment– –Zore
BEDFORD, Mass., September 02, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare
BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The g
The Dravet syndrome market is poised for steady growth, driven by increasing disease awareness, earlier genetic diagnosis, and the expanding adoption of targeted anti-seizure therapies. The introduction of innovative treatments, including Zorevunersen (STK-001) (Stoke Therapeutics and Biogen), Bexicaserin (LP352) (Lundbeck), Clemizole Hydrochloride (EPX-100) (Harmony Biosciences), ETX101 (Encoded Therapeutics), and others, is expected to improve patient outcomes and expand the treatment landscap
Stoke Therapeutics (NASDAQ:STOK) shares gained 1. 4% in pre-market trading after JPMorgan initiated coverage of the biotechnology company with an Overweight rating and a $40 price target, adding another positive Wall Street view to the outlook for the RNA-focused drug developer.
This is the newest page. Registered accounts read further back.